Investigating how gut bacteria affect colitis caused by cancer treatments
Microbiota-Immune Interactions in CTLA-4 Antibody Blockade-Induced Colitis
This study is looking at how the bacteria in your gut and your immune system work together when you're getting a specific cancer treatment, to see why some people develop colitis, which is a painful inflammation that can interrupt their therapy, and the goal is to find ways to prevent or manage this issue for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11119028 on NIH RePORTER |
What this research studies
This research explores the interactions between gut microbiota and the immune system in patients receiving CTLA-4 antibody treatments for cancer. It aims to understand how these treatments can lead to colitis, a severe inflammatory condition that may force patients to stop their cancer therapy. By using specially designed mice that mimic human gut bacteria, the study will investigate the immune pathways involved in this adverse effect. The findings could help identify ways to prevent or manage colitis in patients undergoing cancer immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving CTLA-4 antibody treatments who may be at risk for developing colitis.
Not a fit: Patients who are not receiving CTLA-4 antibody treatments or those without a history of immune-related adverse events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of colitis in cancer patients, allowing them to continue their life-saving treatments.
How similar studies have performed: Previous research has shown that understanding microbiota-immune interactions can lead to significant advancements in managing immune-related adverse events in cancer therapy.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Nunez, Gabriel — University of Michigan at Ann Arbor
- Study coordinator: Nunez, Gabriel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.